Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1/2. fázis

Effect of Rimonabant on Hand Function in Patients With Spinal Cord Injury

A legfontosabb adatok

Ki végzi
Sinfatin S.L
Hol
Spanyolország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
1/2. fázis
Résztvevők
8 fő, tervezett
Kezdés
2026. máj. 13.
Várható befejezés
2027. aug.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Rimonabant
A regiszteradat frissítve
2026. október 21.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Age between 18 and 75 years
  • At least 2 months since spinal cord injury
  • Cervical spinal cord injury (C1-C8) with AIS A-D
  • Muscle strength should be within a range of 5 to 40 points on the UEMS score
  • Capacity to provide informed consent

Ki nem vehet részt

  • History of severe psychiatric disorders, major depression or prior suicide attempts
  • Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort)
  • Participation in another clinical trial with pharmacological intervention within the month prior to enrolment
  • Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines-i.e., those with a failure rate of less than 1 % per year when used consistently and correctly (1); A woman is considered fertile if she is physiologically capable of becoming pregnant, from menarche until postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A woman is considered postmenopausal after spontaneous amenorrhea for at least 12 consecutive months with no alternative medical cause. An elevated follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to support the diagnosis in women not using hormonal contraception or hormone replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is not sufficient; Acceptable highly effective contraceptive methods include:; Combined hormonal contraception (containing estrogen and progestogen) associated with ovulation inhibition, administered orally, vaginally, or transdermal; Progestogen-only hormonal contraception associated with ovulation inhibition (oral, injectable, or implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner: provided this is the participant's sole sexual partner and the vasectomy has been medically confirmed as successful; Sexual abstinence: refraining from heterosexual intercourse during the entire treatment and follow-up period
  • Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease
  • Known allergy to rimonabant or any of the excipients used
  • Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes
  • Contraindications for transcranial magnetic stimulation (TMS), such as metal implants in the head, pacemakers, epileptic seizures in the last two years, or other implanted electronic devices
  • High suicide risk assessed by C-SSRS
  • Body Mass Index (BMI) > 40 kg/m²
  • Pregnancy or breastfeeding
  • Inability to attend hospital visits

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an one arm study to be conducted in spinal cord injury patients. The goal of this clinical trial is to learn if rimonabant improves hand motor and performance function in patients with cervical spinal cord injury. It will also learn about the safety of rimonabant.

A teljes eredeti leírásKevesebb

Participants will: Take 5 mg of rimonabant every day for 90 days. Visit the clinic once every 15-30 days for checkups and tests.

A vizsgálat csoportja

  • TreatmentA vizsgált kezelés

    This arm will receive two tablets of rimonabant 2.5 mg (total of 5 mg), once daily for 90 days

    Kezelés: Rimonabant

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Exploratory Study on the Effect of Rimonabant on Hand Function in Patients With Spinal Cord Injury (RIMOHANDOPEN)
A regiszteradat frissítve
2026. október 21.